[Lepu Medical: Subsidiary MWN110 injection has been approved for clinical trials by the U.S. FDA] On September 28, Lepu Medical (300003.SZ) announced that the company’s controlled subsidiary Shanghai Minwei Biotech has received a notice from the U.S. FDA agreeing to conduct clinical trials of MWN110 injection. The drug is a monoclonal antibody targeting ActRIIA/B. The applied indication is overweight or obesity. It has global intellectual property rights and has been approved by CDE for clinical trials in July 2026. Non-clinical studies have shown that the drug alone can significantly reduce body fat percentage, weight and increase muscle mass, while combined use with semaglutide can inhibit muscle loss. At present, no similar drugs have been approved for marketing at home or abroad.